Advertisements

Cel-Sci Corporation ($0.001 Par Value) (CVM) Stock Quote

Detailed Quote for Cel-Sci Corporation ($0.001 Par Value) (CVM)
$ 1.8693   0.0693 (+3.85%) Volume: 376.01k 4:00 PM EDT Oct 20, 2017
Today 5d 1m 3m 1y more
Last Price
1.8693
Change $
0.0693
Change %
3.85%
Tick
N/A
Bid
N/A
Bid Size
0
Ask
N/A
Ask Size
0
Open
1.80
High
1.92
Low
1.79
Prev Close
1.80
Last Trade
10/20/17
Volume
376.01k
52 Wk Hi
7.49749994
52 Wk Low
1.46000003
Market Cap
18.85m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
10,082,397
EPS (TTM)
-1.58000004
PE Ratio
N/A
Exchange
NYSE American
News and Media for Cel-Sci Corporation ($0.001 Par Value) (CVM)
Sector News | Topic News
News for Cel-Sci Corporation ($0.001 Par Value) (CVM)
Tue, Oct 10, 2017
9:19 AM Premarket Gainers as of 9:05 am - SeekingAlpha
8:30 AM CEL-SCI Granted European Patent for Multikine's Mechanism of Action in Making Tumors 'Visible' to the Immune System - Business Wire
Thu, Oct 05, 2017
9:45 AM CEL-SCI Announces Update on Ongoing Arbitration against Former Clinical Research Organization - Business Wire
Tue, Sep 19, 2017
9:00 AM CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development of Rheumatoid Arthritis Vaccine - Business Wire
Mon, Sep 11, 2017
9:00 AM CEL-SCI to Present Today at the 19th Annual Rodman & Renshaw Global Investment Conference - Business Wire
Wed, Aug 30, 2017
8:00 AM CEL-SCI to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 11, 2017 - Business Wire
Tue, Aug 29, 2017
10:15 AM CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued in December 2016 - Business Wire
Wed, Aug 23, 2017
12:47 PM Midday Gainers / Losers - SeekingAlpha
9:13 AM CEL-SCI announces private $3.5M capital raise at $2/share - SeekingAlpha
9:00 AM CEL-SCI Announces $3.5 Million Registered Direct Offering - Business Wire
Fri, Aug 18, 2017
12:40 PM Midday Gainers / Losers - SeekingAlpha
Wed, Aug 16, 2017
11:13 AM Healthcare - Top 5 Gainers / Losers as of 11:10 - SeekingAlpha
Tue, Aug 15, 2017
8:10 AM Today's Research Reports on Stocks to Watch: Marinus Pharmaceuticals and CEL-SCI Corporation - ACCESSWIRE IA
Mon, Aug 14, 2017
12:46 PM Midday Gainers / Losers - SeekingAlpha
9:22 AM Premarket Gainers as of 9:05 am - SeekingAlpha
7:50 AM FDA removes clinical hold on CEL-SCI's late-stage study of Multikine in head and neck cancer; shares ahead 58% premarket - SeekingAlpha
7:00 AM U.S. FDA Removes Clinical Hold on CEL-SCI's Phase 3 Head & Neck Cancer Trial - Business Wire
Wed, Aug 09, 2017
5:23 PM Cel-Sci reports Q3 results - SeekingAlpha
4:54 PM CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016 - Business Wire
4:20 PM CEL-SCI Corporation Reports Third Quarter Fiscal Year 2017 Financial Results - Business Wire
More News for CVM >>

Tags for Cel-Sci Corporation ($0.001 Par Value)

Research stocks or mutual funds related to Cel-Sci Corporation ($0.001 Par Value) by keywords or tags. Find companies that have a similar focus to CVM. The keywords below have been associated to CVM by either user submission or electronic means.

biotech research clinical trial enrollment clinical research trial clinical research software laboratory research arthritis causes corporate financial clinical cost disney annual report pharmaceutical study research institutes clinical research consulting Medical Laboratories (8071) annual report asthma clinical trial Biological Products phase iii clinical trials financial report cra clinical research research clinical research technology research phase 3 clinical trials clinical trials manager fda clinical trial medical research immunology reactive arthritis biotechnology research what causes arthritis physician clinical trials Drugs comfort research annual report of company corporate annual report 3m annual report clinical trials recruitment clinical trials conference clinical metabolic research clinical study agreements clinical data Healthcare clinical trial publication clinical research network monitoring clinical research financial statement software clinical research nurse Except Diagnostic Substances (2836) financial statement